GlassScriptPhysician profile
Houston Bogus
NPI 1669418679
$4,884.81
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $938 · 2021: $1,573 · 2022: $1,272 · 2023: $49.22 · 2024: $37.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,456.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $622.19 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $620.92 | 2019-2024 | Trulance |
| Daiichi Sankyo INC. | $279.24 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $257.09 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $216.58 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $158.39 | 2019-2021 | |
| Braintree Laboratories, INC. | $126.57 | 2019-2021 | |
| Boston Scientific Corporation | $98.46 | 2019 | |
| Janssen Biotech, INC. | $96.73 | 2019-2022 | |
| Gilead Sciences, INC. | $96.14 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $86.88 | 2022 | |
| Pfizer INC. | $86.02 | 2019-2021 | |
| Redhill Biopharma INC. | $79.88 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Alfasigma USA, INC. | $72.24 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.14 | 2019-2021 | |
| Vivus LLC | $61.85 | 2022 | |
| Evoke Pharma, INC. | $60.03 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $40.06 | 2021 | |
| Nestle Healthcare Nutrition INC. | $37.08 | 2021 | |
| Shire North American Group INC | $35.49 | 2019 | |
| Celgene Corporation | $33.77 | 2021-2022 | |
| Dynavax Technologies Corporation | $28.17 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $26.30 | 2019 | |
| Pinnacle Biologics, INC | $21.82 | 2022 | |
| Ardelyx, INC. | $19.90 | 2022 | |
| Medtronic, INC. | $19.90 | 2023 | Endoflip |
| Genzyme Corporation | $19.25 | 2022 | |
| American Regent | $18.15 | 2024 | Injectafer |
| Organon LLC | $17.62 | 2022 | |
| Exact Sciences Corporation | $15.05 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Houston Bogus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.